INGN icon

Inogen

8.54 USD
-0.02
0.23%
At close Updated Sep 12, 4:00 PM EDT
Pre-market
After hours
8.54
0.00
0%
1 day
-0.23%
5 days
4.66%
1 month
12.66%
3 months
32.61%
6 months
8.38%
Year to date
-7.07%
1 year
-24.22%
5 years
-69.29%
10 years
-84.39%
 

About: Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.

Employees: 766

0
Funds holding %
of 7,462 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2.34% more ownership

Funds ownership: 70.82% [Q1] → 73.16% (+2.34%) [Q2]

7% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 45

3% more capital invested

Capital invested by funds: $134M [Q1] → $138M (+$4.36M) [Q2]

2% less funds holding

Funds holding: 127 [Q1] → 124 (-3) [Q2]

13% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 15

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$14
64% upside
Avg. target
$14
64% upside
High target
$14
64% upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
B. Riley Securities
Anderson Schock
$14
Buy
Initiated
16 Jun 2025

Financial journalist opinion

Based on 3 articles about INGN published over the past 30 days

Positive
Zacks Investment Research
5 days ago
Wall Street Analysts See a 35.64% Upside in Inogen (INGN): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 35.6% in Inogen (INGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 35.64% Upside in Inogen (INGN): Can the Stock Really Move This High?
Negative
Zacks Investment Research
11 days ago
3 Top Medical Instruments Stocks Defying Tariff Pressure With GenAI
Teleflex, Integer Holdings and Inogen are defying tariff and supply chain headwinds with genAI-driven momentum within the Medical Instruments industry.
3 Top Medical Instruments Stocks Defying Tariff Pressure With GenAI
Positive
Zacks Investment Research
23 days ago
Wall Street Analysts Think Inogen (INGN) Could Surge 49.25%: Read This Before Placing a Bet
The mean of analysts' price targets for Inogen (INGN) points to a 49.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Inogen (INGN) Could Surge 49.25%: Read This Before Placing a Bet
Neutral
Seeking Alpha
1 month ago
Inogen, Inc. (INGN) Q2 2025 Earnings Call Transcript
Inogen, Inc. (NASDAQ:INGN ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Kevin R. M. Smith - President, CEO & Director Lorna Williams - Corporate Participant Michael J.
Inogen, Inc. (INGN) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Inogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/Y
INGN stock rises as Q2 loss narrows and revenue climbs 4% year over year, driven by strong B2B demand despite DTC and rental declines.
Inogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/Y
Neutral
Zacks Investment Research
1 month ago
Inogen (INGN) Reports Q2 Loss, Beats Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.24 per share a year ago.
Inogen (INGN) Reports Q2 Loss, Beats Revenue Estimates
Neutral
Business Wire
1 month ago
Inogen Announces Second Quarter 2025 Financial Results
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Announces Second Quarter 2025 Financial Results; Delivered strong top-line results; raising full year 2025 revenue expectations.
Inogen Announces Second Quarter 2025 Financial Results
Neutral
Business Wire
1 month ago
Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025.
Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025
Positive
Zacks Investment Research
1 month ago
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Neutral
Business Wire
2 months ago
Inogen Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy
GOLETA, Calif.--(BUSINESS WIRE)---- $INGN #AirwayClearance--Inogen Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy.
Inogen Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy
Charts implemented using Lightweight Charts™